达雷妥尤单抗治疗经重度预处理且骨髓浆细胞浸润高的轻链型(AL)淀粉样变性患者,克隆性和肾脏缓解率高
本报告评估28天周期达雷妥尤单抗(单药或联合硼替佐米或来那度胺)在72例既往接受过治疗的多发性骨髓瘤合并AL淀粉样变性患者中的安全性和疗效。8次输注后59例(82%)达血液学缓解,16次输注后22例(30%)达完全缓解、21例(29%)达非常好的部分缓解;可评估患者中心脏缓解11/37(29%),肾脏缓解23/38(60%)。
要点
- 8次输注后59例(82%)达血液学缓解,其中完全缓解12例(16%)、非常好的部分缓解30例(42%)。
- 16次输注后缓解质量提高,完全缓解22例(30%)、非常好的部分缓解21例(29%)。
- 心脏缓解11/37例(29%),肾脏缓解23/38例(60%)。
核心结论
- 达雷妥尤单抗在复发/难治性AL淀粉样变性且骨髓浆细胞负荷高的重度预处理患者中高度有效,肾脏缓解通常少见但本研究中频繁观察到。
研究设计与样本
- 评估28天周期达雷妥尤单抗(单药或联合硼替佐米或来那度胺)在72例既往接受过治疗的多发性骨髓瘤合并AL淀粉样变性患者中的安全性和疗效。
- 50例(69%)对末线治疗难治。
主要发现
- 8次输注后59例(82%)达血液学缓解,其中完全缓解12例(16%)、非常好的部分缓解30例(42%)。
- 16次输注后22例(30%)达完全缓解、21例(29%)达非常好的部分缓解。
- 心脏缓解11/37例可评估患者(29%),肾脏缓解23/38例(60%)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Daratumumab demonstrated activity in the treatment of AL amyloidosis in two recently concluded phase II clinical trials in relapsed and refractory patients. Its role in upfront therapy is under evaluation in a phase III study. In this report we evaluated the safety and efficacy of 28-day cycles of daratumumab (single agent or combined with bortezomib or lenalidomide) in 72 previously treated patients with multiple myeloma and AL amyloidosis. Fifty (69%) were refractory to the last line of therapy. After eight infusions of daratumumab, 59 patients (82%) achieved a hematologic response, with 12 (16%) complete responses (CRs) and 30 (42%) very good partial responses (VGPRs). After 16 infusions, the quality of response improved with 22 patients (30%) achieving CR and 21 (29%) attaining VGPR. Cardiac response was observed in 11 of 37 evaluable patients (29%) and renal response in 23 of 38 patients (60%). Daratumumab is highly effective in heavily pretreated patients with relapsed/refractory AL amyloidosis and high bone marrow plasma cell burden. Renal responses, which are usually rare in this setting, were frequently observed.
引用
- Milani P, Fazio F, Basset M, et al. High rate of profound clonal and renal responses with daratumumab treatment in heavily pre-treated patients with light chain (AL) amyloidosis and high bone marrow plasma cell infiltrate. Am J Hematol. 2020. PMID: 32282971. doi:10.1002/ajh.25828
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。